IMMUPHARMA PLC – Bioanalytical Cro Partner For Kapiglucagon
RNS Number : 8451P Immupharma PLC 10 August 2026 This announcement contains inside information for the purposes of the
RNS Number : 8451P Immupharma PLC 10 August 2026 This announcement contains inside information for the purposes of the
RNS Number : 2794N Immupharma PLC 22 July 2026 This announcement contains inside information for the purposes of the
RNS Number : 4356J Immupharma PLC 25 June 2026 This announcement contains inside information for the purposes of the
RNS Number : 9924G Immupharma PLC 04 June 2026 RNS REACH: RELEASE 4 June 2026
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to present a comprehensive and detailed update of the significant positive progress achieved since major changes in the Board and Senior Management re-structuring in August 2021.
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to provide an update in respect to a number of corporate and scientific activities within the business over the last period.
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2020 (the “Period”).
AIM-listed specialist drug discovery and development company ImmuPharma has been out of favour with investors recently and the shares are languishing at close to all-time lows.
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2020 (the “Period”).
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has entered into a subscription agreement with Lanstead Capital Investors LP (“Lanstead”), an institutional investor, together with a related sharing agreement, raising approximately £2.66 million.